Related Experiment Video
Updated: Jul 30, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Immunohistochemical and molecular evaluation of TUSC2 expression in breast cancer
Leyla Tekin1, Tuba Edgünlü2, Deniz Genç3
1Faculty of Medicine, Pathology Department, Muğla Sıtkı Koçman University, Muğla, Turkey. dr.ltekin@hotmail.com.
Objective:
Tumor suppressor candidate 2 has shown to be deleted in lung, colon, and bladder cancer types. In the present study, we aimed to investigate the expression of TUSC2 in breast cancer.
Materials And Methods:
A total of thirty patients with breast cancer were included in the study. Normal and tumor tissue samples from fresh mastectomy materials were stored at -80 C until the number of cases was completed for gene expression analysis. Histopathological examination was carried out with routine hematoxylin & eosin method. TUSC2 staining was performed for immunohistochemical analysis.
Results:
The tumors of thirteen patients were Luminal A, fourteen patients were Luminal B, one patient was cerbB2(+), and tumors of two patients were triple-negative. Ki67 proliferation index was less than 14% in fifteen cases and tumor size was less than 2 cm in seven cases. Lymphovascular invasion and lymph node metastasis were present in thirteen cases. Statistically, TUSC2 expression significantly decreased or was lost in breast tumor tissues compared to normal tissues (p < 0.0001). TUSC2 expression decreased as the Ki67 proliferation index increased (p = 0.0003), and TUSC2 expression decreased as tumor size increased (p = 0.0483). The loss or decrease in the TUSC2 expression was significant as the tumor grade increased (p = 0.3740). Gene expression analysis correlated with immunohistochemistry results.
Conclusion:
The results of the present study demonstrated a decrease or loss of TUSC2 expression in breast cancer tissue compared to normal tissue. A correlation was found between TUSC2 expression and Ki67 proliferation index and tumor size.
Insights
Tumor suppressor candidate 2 (TUSC2) expression is significantly decreased or lost in breast cancer tissues. Lower TUSC2 levels correlate with increased tumor size and proliferation, suggesting its role in breast cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Tumor suppressor candidate 2 (TUSC2) is frequently deleted in lung, colon, and bladder cancers.
- Understanding TUSC2's role in breast cancer is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression levels of TUSC2 in breast cancer tissues.
- To correlate TUSC2 expression with key clinicopathological features of breast cancer.
Main Methods:
- Gene expression analysis and immunohistochemistry were performed on 30 breast cancer patient samples.
- TUSC2 protein expression was assessed via immunohistochemical staining.
- Histopathological examination and Ki67 proliferation index were evaluated.
Main Results:
- TUSC2 expression was significantly decreased or lost in breast tumor tissues compared to normal tissues (p < 0.0001).
- Decreased TUSC2 expression correlated with increased Ki67 proliferation index (p = 0.0003) and larger tumor size (p = 0.0483).
- Gene expression data aligned with immunohistochemistry findings.
Conclusions:
- TUSC2 expression is significantly reduced in breast cancer.
- TUSC2 downregulation is associated with aggressive tumor characteristics, including higher proliferation and larger tumor size.
- TUSC2 may function as a tumor suppressor in breast cancer.
More Related Videos
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
